Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

429
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
429
Cancer Survival Analysis01:21

Cancer Survival Analysis

357
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
357
Hazard Ratio01:12

Hazard Ratio

136
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
136
Stereotypes, Prejudice, and Discrimination02:55

Stereotypes, Prejudice, and Discrimination

90.2K
Humans are very diverse and although we share many similarities, we also have many differences. The social groups we belong to help form our identities (Tajfel, 1974). These differences may be difficult for some people to reconcile, which may lead to prejudice toward people who are different. Prejudice is a negative attitude and feeling toward an individual based solely on one’s membership in a particular social group (Allport, 1954; Brown, 2010). Prejudice is common against people who...
90.2K
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

200
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
200
Abnormal Proliferation02:23

Abnormal Proliferation

4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

NCCN Guidelines® Insights: Prostate Cancer, Version 5.2026.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

Dysregulation of estrogen signaling and HSD17B7 in the prostate stroma of African American men.

Endocrinology·2026
Same author

Social determinants of health in lung cancer surgery: perspectives from family caregivers, clinicians, and healthcare system administrators.

Frontiers in public health·2026
Same author

Prostate Cancer, Version 3.2026, NCCN Clinical Practice Guidelines In Oncology.

Journal of the National Comprehensive Cancer Network : JNCCN·2025
Same author

Oncological outcomes after tailored PSMA-PET-guided treatment in biochemical relapse after prostatectomy (PSICHE Trial-NCT 05022914).

La Radiologia medica·2025
Same author

Radiogenomic Profiling of Prostate Tumors prior to External Beam Radiotherapy Converges on a Transcriptomic Signature of TGF-β Activity Driving Tumor Recurrence.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025
Same journal

Present and Emerging Strategies for Disease Assessment in Hodgkin Lymphoma.

Cancer journal (Sudbury, Mass.)·2026
Same journal

Nodular Lymphocyte-predominant Hodgkin Lymphoma: Incidence, Pathogenesis, Management.

Cancer journal (Sudbury, Mass.)·2026
Same journal

Management of Classic Hodgkin Lymphoma in Special Clinical Situations.

Cancer journal (Sudbury, Mass.)·2026
Same journal

Older Patients With Hodgkin Lymphoma: A Contemporary Review.

Cancer journal (Sudbury, Mass.)·2026
Same journal

Adolescent and Young Adult Patients With Classical Hodgkin Lymphoma: A Review as a Case Study in AYA Cancer Care.

Cancer journal (Sudbury, Mass.)·2026
Same journal

Hodgkin Lymphoma: Management of Patients Who Fail Primary Therapy.

Cancer journal (Sudbury, Mass.)·2026
See all related articles

Related Experiment Video

Updated: Jul 11, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.1K

Prostate Cancer, Race, and Health Disparity: What We Know.

Mack Roach1, Pamela W Coleman2, Rick Kittles3

  • 1From the Particle Therapy Research Program & Outreach, Department of Radiation Oncology, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA.

Cancer Journal (Sudbury, Mass.)
|November 14, 2023
PubMed
Summary
This summary is machine-generated.

Prostate cancer (PCa) outcomes show disparities in African American men, influenced by both genetic factors and systemic inequities. Addressing social determinants of health and ensuring equitable care are crucial for improving prostate cancer survival rates.

More Related Videos

Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking
07:34

Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking

Published on: November 17, 2023

703
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

16.6K

Related Experiment Videos

Last Updated: Jul 11, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.1K
Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking
07:34

Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking

Published on: November 17, 2023

703
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

16.6K

Area of Science:

  • Oncology
  • Health Disparities Research
  • Genetics

Background:

  • Prostate cancer (PCa) disproportionately affects African American men, often presenting at advanced stages.
  • The disparity in PCa outcomes raises questions about the interplay of innate biology, genetics, and socioeconomic factors.
  • Race is a social construct, yet racism demonstrably impacts health outcomes and biological processes.

Purpose of the Study:

  • To explore the complex factors contributing to prostate cancer disparities in African American men.
  • To differentiate the roles of genetic predisposition versus social determinants and healthcare access in PCa outcomes.
  • To examine the influence of race and racism on prostate cancer biology and clinical presentation.

Main Methods:

  • Review of genetic studies identifying PCa risk alleles in populations of West African descent.
  • Analysis of population-level differences in tumor immunology.
  • Examination of the impact of structural racism and healthcare access on PCa clinical outcomes.

Main Results:

  • Populations of West African descent show an enrichment of prostate cancer risk alleles.
  • Differences in tumor immunology exist at the population level.
  • Evidence suggests that comparable healthcare quality leads to comparable PCa outcomes, irrespective of race.

Conclusions:

  • Both genetic predispositions and social/health injustices contribute to prostate cancer disparities.
  • Structural racism plays a significant role in observed differences in PCa clinical outcomes.
  • Equitable access to high-quality healthcare is paramount in mitigating prostate cancer outcome disparities.